Clinical Utility of Haptoglobin in Combination with CEA, NSE and CYFRA21-1 for Diagnosis of Lung Cancer

Wang, Bing; He, Yujie; Tian, Ying-Xing; Yang, Rui‐Ning; Zhu, Yue-Rong; Qian, Hong

doi:10.7314/apjcp.2014.15.22.9611

Cited by 46 publications

(32 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding of our study may suggest a cost-effective method for NSCLC patients to decide who should run for this expensive assay. Tumor markers are always used as biomarkers for earlier diagnosis, treatment efficacy and prognosis in NSCLC [ 4 – 5 , 12 , 37 – 38 ]. As serum CEA is associated with CTCs, it may be possible to recommend the CellSearch assay for those NSCLC patients who are CEA-positive.…”

Section: Discussionmentioning

confidence: 99%

Combination of Circulating Tumor Cells with Serum Carcinoembryonic Antigen Enhances Clinical Prediction of Non-Small Cell Lung Cancer

Chen

Wang

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) have emerged as a potential biomarker in the diagnosis, prognosis, treatment, and surveillance of lung cancer. However, CTC detection is not only costly, but its sensitivity is also low, thus limiting its usage and the collection of robust data regarding the significance of CTCs in lung cancer. We aimed to seek clinical variables that enhance the prediction of CTCs in patients with non-small cell lung cancer (NSCLC). Clinical samples and pathological data were collected from 169 NSCLC patients. CTCs were detected by CellSearch and tumor markers were detected using the Luminex xMAP assay. Univariate analyses revealed that histology, tumor stage, tumor size, invasiveness, tumor grade and carcinoembryonic antigen (CEA) were associated with the presence of CTCs. However, the level of CTCs was not associated with the degree of nodal involvement (N) or tumor prognostic markers Ki-67, CA125, CA199, Cyfra21-1, and SCCA. Using logistic regression analysis, we found that the combination of CTCs with tumor marker CEA has a better disease prediction. Advanced stage NSCLC patients with elevated CEA had higher numbers of CTCs. These data suggest a useful prediction model by combining CTCs with serum CEA in NSCLC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination of Circulating Tumor Cells with Serum Carcinoembryonic Antigen Enhances Clinical Prediction of Non-Small Cell Lung Cancer

Chen

Wang

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…CK19 has been reported to be over-expressed in many lung cancer tissue specimens (11,12), which results in an increase of the plasma CYFRA21-1 values (13). Some studies reported that CYFRA21-1 can be useful for pathological typing and assessment of treatment efficacy of NSCLC (14,15).…”

Section: Introductionmentioning

confidence: 99%

Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study

et al. 2016

View full text Add to dashboard Cite

“…For example, the ground-glass opacity (GGO) or ground-glass nodule (GGN) is usually adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) or atypical adenomatous hyperplasia (AAH) [30] . Higher false positive and false negative rate by using traditional biomarkers like carcino-embryonic antigen (CEA), neuro-specific enolase (NSE) and cytokeratin 19 (CYFRA-211) make the diagnosis more difficult [31,32] . These biomarkers are useless in early diagnosis of lung cancer.…”

Section: Discussionmentioning

confidence: 99%

RNF213 gene mutation of circulating tumor DNA in early diagnosis of NSCLC using targeted next-generation sequencing

Jiang¹,

Zhao²,

P³

et al. 2019

Preprint

View full text Add to dashboard Cite

Introduction To distinguish early stage lung cancer from benign disease of the lung nodules, especially the lesions with ground-glass opacity (GGO) or ground-glass nodule (GGN), we assessed gene mutations of the ctDNA in peripheral blood by using targeted next-generation sequencing (NGS). Methods Single lung nodule patients without mediastinal lymph nodes or symptoms hardly diagnosed by chest CT and biomarker of lung cancer were enrolled. All patients received minimally invasive surgery but refused preoperative biopsy. Gene mutations of pre-operative blood samples were detected by targeted NGS. Mutations with statistical differences were screened in lung cancer and benign disease grouped by postoperative pathology. Gene expression was determined by immunohistochemistry. Highly expressed genes were selected as biomarkers to verify the mutations in peripheral blood. Results In training set, RNF213, KMT2D, CSMD3 and LRP1B genes mutated more frequently in early stage lung cancer (25cases) than benign nodules (18cases) (P<0.05). High expressions of RNF213 gene in lung cancers and low expressions in benign diseases were evaluated by immunohistochemistry. RNF213 gene mutated in 25% lung cancer samples in the validation set of 28 samples and showed high specificity (100%) and low sensibility (25.9%). In GGO and GGN patients, RNF213 mutated more frequently in early stage lung cancer compared to benign diseases (P<0.05). Conclusions RNF213 gene mutation was observed more frequently in early stage lung cancer, but rather than benign nodules. Mutation of RNF213 gene in peripheral blood may be a high specificity biomarker and valuable for early diagnosis of lung cancer.

show abstract

Clinical Utility of Haptoglobin in Combination with CEA, NSE and CYFRA21-1 for Diagnosis of Lung Cancer

Cited by 46 publications

References 16 publications

Combination of Circulating Tumor Cells with Serum Carcinoembryonic Antigen Enhances Clinical Prediction of Non-Small Cell Lung Cancer

Combination of Circulating Tumor Cells with Serum Carcinoembryonic Antigen Enhances Clinical Prediction of Non-Small Cell Lung Cancer

Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study

RNF213 gene mutation of circulating tumor DNA in early diagnosis of NSCLC using targeted next-generation sequencing

Contact Info

Product

Resources

About